The National Institute for Health Care Excellence (NICE) today publishes draft guidance for life-extending drug, Xofigo® (radium-223 dichloride) now allowed for men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases where docetaxel is contraindicated or is not suitable. Due to Tackle’s help in campaigning throughout the approval process, this medicine is now made available to a larger group of men who have not taken docetaxel and for men in Wales who aren’t suitable for docetaxel.
Hugh Gunn, Trustee, commented: “Tackle Prostate Cancer is delighted that NICE have relaxed the ruling on Radium-223, which was only previously available to patients who had already received the chemotherapy drug docetaxel. NICE have announced today that it can now be given to patients irrespective of whether they have received docetaxel, providing there is no visceral (soft tissue) metastasis.
This is a welcome and sensible improvement that Tackle has worked hard to achieve and it will greatly benefit prostate cancer patients who have limited treatment options open to them.”
Tackle successfully continues to campaign, making more medicines available for prostate cancer patients, giving vital lifelines to men with limited treatment options.